JP Morgan Chase’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.19M | Buy |
1,058,067
+445,588
| +73% | +$2.85M | ﹤0.01% | 2990 |
|
|
2026
Q1 | $3.43M | Sell |
612,479
-282,580
| -32% | -$1.87M | ﹤0.01% | 3671 |
|
|
2025
Q4 | $7.03M | Sell |
895,059
-10,017
| -1% | -$78.8K | ﹤0.01% | 3014 |
|
|
2025
Q3 | $7.37M | Sell |
905,076
-127,186
| -12% | -$845K | ﹤0.01% | 3001 |
|
|
2025
Q2 | $4.82M | Sell |
1,032,262
-1,082,447
| -51% | -$4.96M | ﹤0.01% | 3208 |
|
|
2025
Q1 | $11.6M | Buy |
2,114,709
+1,071,268
| +103% | +$4.32M | ﹤0.01% | 2409 |
|
|
2024
Q4 | $3.54M | Buy |
1,043,441
+651,481
| +166% | +$2.1M | ﹤0.01% | 3683 |
|
|
2024
Q3 | $1.12M | Buy |
391,960
+67,557
| +21% | +$174K | ﹤0.01% | 4397 |
|
|
2024
Q2 | $730K | Sell |
324,403
-49,952
| -13% | -$101K | ﹤0.01% | 4470 |
|
|
2024
Q1 | $827K | Buy |
374,355
+51,919
| +16% | +$134K | ﹤0.01% | 4478 |
|
|
2023
Q4 | $758K | Buy |
322,436
+205,480
| +176% | +$379K | ﹤0.01% | 4521 |
|
|
2023
Q3 | $218K | Sell |
116,956
-185,400
| -61% | -$425K | ﹤0.01% | 5020 |
|
|
2023
Q2 | $792K | Sell |
302,356
-463,935
| -61% | -$1.18M | ﹤0.01% | 4222 |
|
|
2023
Q1 | $1.25M | Buy |
766,291
+671,873
| +712% | +$841K | ﹤0.01% | 3885 |
|
|
2022
Q4 | $126K | Buy |
94,418
+10,096
| +12% | +$14.3K | ﹤0.01% | 5257 |
|
|
2022
Q3 | $132K | Buy |
84,322
+4,712
| +6% | +$7.79K | ﹤0.01% | 5159 |
|
|
2022
Q2 | $123K | Buy |
79,610
+60,955
| +327% | +$129K | ﹤0.01% | 5318 |
|
|
2022
Q1 | $48K | Buy |
18,655
+5,398
| +41% | +$13.2K | ﹤0.01% | 5816 |
|
|
2021
Q4 | $39K | Buy |
13,257
+8,629
| +186% | +$18.6K | ﹤0.01% | 6029 |
|
|
2021
Q3 | $11K | Buy |
4,628
+1,509
| +48% | +$4.38K | ﹤0.01% | 6160 |
|
|
2021
Q2 | $13K | Sell |
3,119
-14,115
| -82% | -$53.9K | ﹤0.01% | 6007 |
|
|
2021
Q1 | $78K | Sell |
17,234
-3,115
| -15% | -$16.8K | ﹤0.01% | 5441 |
|
|
2020
Q4 | $100K | Buy |
20,349
+3,215
| +19% | +$16.1K | ﹤0.01% | 4994 |
|
|
2020
Q3 | $100K | Sell |
17,134
-2,639,449
| -99% | -$10.6M | ﹤0.01% | 4696 |
|
|
2020
Q2 | $7.07M | Buy |
2,656,583
+2,648,064
| +31,084% | +$9.22M | ﹤0.01% | 2181 |
|
|
2020
Q1 | $17K | Sell |
8,519
-222
| -3% | -$955 | ﹤0.01% | 4985 |
|
|
2019
Q4 | $62K | Hold |
8,741
| – | – | ﹤0.01% | 5055 |
|
|
2019
Q3 | $86K | Buy |
8,741
+1,417
| +19% | +$15.9K | ﹤0.01% | 4960 |
|
|
2019
Q2 | $79K | Sell |
7,324
-2,119
| -22% | -$22.2K | ﹤0.01% | 5011 |
|
|
2019
Q1 | $95K | Buy |
9,443
+7,734
| +453% | +$99.1K | ﹤0.01% | 4903 |
|
|
2018
Q4 | $29K | Buy |
1,709
+177
| +12% | +$3.55K | ﹤0.01% | 5243 |
|
|
2018
Q3 | $27K | Buy |
+1,532
| New | +$33.3K | ﹤0.01% | 5364 |
|
Other funds holding XERS
RA
JP Morgan Chase's XERS Position: Q2 2026 in Review
JP Morgan Chase increased its Xeris Biopharma Holdings (XERS) stake by 73% in Q2 2026, buying an estimated $2.85M and bringing the position to 1,058,067 shares worth $8.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2990.
JP Morgan Chase first reported a position in XERS in Q3 2018 and has held it in 32 quarters since. The position peaked at $11.6M in Q1 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.
- JP Morgan Chase held 1,058,067 shares of Xeris Biopharma Holdings worth $8.19M as of Q2 2026.
- JP Morgan Chase bought 445,588 Xeris Biopharma Holdings shares in Q2 2026, an estimated $2.85M.
- Xeris Biopharma Holdings made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2990 holding.
- JP Morgan Chase first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 32 quarters since.
- JP Morgan Chase's Xeris Biopharma Holdings position peaked at $11.6M in Q1 2025.
- 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.